The 5 most recent market catalysts affecting $TEMP, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 8, 2026
Corporate Catalyst
Bullish
Impact 55
Tempus AI Expands Data and Sequencing Collaboration with Remix Therapeutics
Tempus AI has expanded its strategic collaboration with Remix Therapeutics, focusing on data and sequencing capabilities. This development is a continuation of an existing relation…
Nov 3, 2026
Corporate Catalyst
Neutral
Impact 65
Analysts Update Ratings and Price Targets for Tempus AI
On November 3, 2026, Tempus AI saw significant analyst activity. Jefferies upgraded its rating from Sell to Hold with a $70 price target, while Cantor Fitzgerald maintained an Over…
Nov 2, 2026
Corporate Catalyst
Neutral
Impact 92
Tempus AI Reports Third Quarter 2026 Financial Results
Tempus AI announced impressive Q3 2026 financial results, with reported adjusted EPS of $0.07 significantly surpassing analyst expectations of a $0.09 loss per share. This strong p…
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 85
Tempus Announces Expanded Collaboration With Merck And Moderna For Potential Commercialization Of Cancer Vaccine Intismeran Autogene; Terms Not Disclosed
This expanded collaboration is a significant positive catalyst for Tempus, Merck, and Moderna. For Tempus, it validates their cancer vaccine platform and provides a clear path to c…
Sep 14, 2026
Corporate Catalyst
Neutral
Impact 55
'Tempus AI Founder Supports Anthropic CEO’s Call for Slowdown' - Bloomberg News
The filing, a Bloomberg article, reports that Eric Lefkofsky, founder of Tempus AI, supports the Anthropic CEO's call for a slowdown in AI development. This matters because it sign…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.